Grace Crawford1, Jessica Weisbrot1, Joseph Bastian1, Alex Flitter1, Nancy C Jao2, Allison Carroll2, Ravi Kalhan3, Frank Leone4, Brian Hitsman2,5, Robert Schnoll1. 1. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA. 2. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 3. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 4. Pulmonary, Allergy, & Critical Care Division, University of Pennsylvania, Philadelphia, PA. 5. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Abstract
INTRODUCTION: The degree to which smokers adhere to pharmacotherapy predicts treatment success. The development of interventions to increase adherence requires identification of predictors of treatment adherence, particularly among specific clinical populations. METHODS: Using data from a 12-week open-label phase of a clinical trial of varenicline for tobacco dependence among cancer patients (N = 207), we examined: (1) the relationship between self-reported varenicline adherence and verified smoking cessation and (2) demographic and disease-related variables, and early changes in cognition, affect, withdrawal, the reinforcing effects of smoking, and medication side effects, as correlates of varenicline adherence. RESULTS: At the end of 12 weeks, 35% of the sample had quit smoking and 52% reported taking ≥80% of varenicline. Varenicline adherence was associated with cessation (p < .001): 58% of participants who were adherent had quit smoking versus 11% of those who were not. Participants who experienced early reductions in depressed mood and satisfaction from smoking and experienced an increase in the toxic effects of smoking, showed greater varenicline adherence (p < .05); the relationship between greater adherence and improved cognition, reduced craving, and reduced sleep problems and vomiting approached significance (p < .10). CONCLUSIONS: Among cancer patients treated for tobacco dependence withvarenicline, adherence is associated with smoking cessation. Initial changes in depressed mood and the reinforcing effects of smoking are predictive of adherence. IMPLICATIONS: The benefits of varenicline for treating tobacco dependence among cancer patients may depend upon boosting adherence by addressing early signs of depression and reducing the reinforcing dimensions of cigarettes.
RCT Entities:
INTRODUCTION: The degree to which smokers adhere to pharmacotherapy predicts treatment success. The development of interventions to increase adherence requires identification of predictors of treatment adherence, particularly among specific clinical populations. METHODS: Using data from a 12-week open-label phase of a clinical trial of varenicline for tobacco dependence among cancerpatients (N = 207), we examined: (1) the relationship between self-reported varenicline adherence and verified smoking cessation and (2) demographic and disease-related variables, and early changes in cognition, affect, withdrawal, the reinforcing effects of smoking, and medication side effects, as correlates of varenicline adherence. RESULTS: At the end of 12 weeks, 35% of the sample had quit smoking and 52% reported taking ≥80% of varenicline. Varenicline adherence was associated with cessation (p < .001): 58% of participants who were adherent had quit smoking versus 11% of those who were not. Participants who experienced early reductions in depressed mood and satisfaction from smoking and experienced an increase in the toxic effects of smoking, showed greater varenicline adherence (p < .05); the relationship between greater adherence and improved cognition, reduced craving, and reduced sleep problems and vomiting approached significance (p < .10). CONCLUSIONS: Among cancerpatients treated for tobacco dependence with varenicline, adherence is associated with smoking cessation. Initial changes in depressed mood and the reinforcing effects of smoking are predictive of adherence. IMPLICATIONS: The benefits of varenicline for treating tobacco dependence among cancerpatients may depend upon boosting adherence by addressing early signs of depression and reducing the reinforcing dimensions of cigarettes.
Authors: Sheryl L Catz; Lisa M Jack; Jennifer B McClure; Harold S Javitz; Mona Deprey; Susan M Zbikowski; Tim McAfee; Julie Richards; Gary E Swan Journal: Nicotine Tob Res Date: 2011-02-24 Impact factor: 4.244
Authors: Amanda R Mathew; Elizabeth Garrett-Mayer; Bryan W Heckman; Amy E Wahlquist; Matthew J Carpenter Journal: Nicotine Tob Res Date: 2017-12-13 Impact factor: 4.244
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321
Authors: Allison J Carroll; Kristine Kim; Andrew Miele; Matthew Olonoff; Frank T Leone; Robert A Schnoll; Brian Hitsman Journal: Addict Behav Date: 2019-04-03 Impact factor: 3.913
Authors: Rebecca L Ashare; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Ronald G Collman; E Paul Wileyto; Robert Schnoll Journal: Drug Alcohol Depend Date: 2019-05-07 Impact factor: 4.492
Authors: Robert Schnoll; Frank Leone; Anna Veluz-Wilkins; Andrew Miele; Anita Hole; Nancy C Jao; E Paul Wileyto; Allison J Carroll; Ravi Kalhan; Jyoti Patel; Corey Langer; Su Fen Lubitz; Brian Hitsman Journal: Psychooncology Date: 2019-01-24 Impact factor: 3.894